Ariel Miller and Hossam Haick 311.
(photo credit: Technion)
The “electronic nose,” developed by a young chemical engineer and his colleagues
at the Technion-Israel Institute of Technology, has been proven to detect lung
and other cancers from breath. It has also succeeded in diagnosing in the same
way multiple sclerosis.
RELATED:Technion’s Shechtman becomes nation’s 10th Nobel laureate Technion named among leading computer universities
The non-invasive technique using sensors, which
has been called a “breakthrough” in early diagnosis of the disease that first
appears in young adults, was reported in the latest issue of the journal ACS
Prof. Hossam Haick, who still in his 30s has
received numerous prestigious scientific awards, developed the electronic sensor
in the Technion’s chemical engineering faculty and the Russell Berrie Institute
for Nanotechnology Research, together with Prof. Ariel Miller of the Technion’s
Rappaport Medical Faculty and Carmel Medical Center in Haifa.
cure has yet been found for MS, in which the immune system of the body
mistakenly regards the myelin coating of nerves as a “stranger” and attacks it,
a number of medications – most of them, like Copaxone, developed in Israel – can
slow and reduce the neurological attacks that can cause loss of muscle function,
paralysis and pain.
Conventional diagnosis of MS, which first appears as
numbed nerves, has been via expensive MRI scanning and the examination of spinal
fluid. But in their first clinical study, Haick and Miller identified organic
compounds in the breath that are a sign of MS. They developed nanometric sensors
and tested them on 34 MS patients and 17 normal volunteers. The results were
found to be accurate.
The researchers predicted that MS could be
diagnosed at an early stage and non-invasively using the sensors.
“It is a
very early stage, and the research will continue with the aim of developing
speedy diagnosis for MS and other chronic neurological diseases. The
sensors could also detect neurological attacks after the disease is diagnosed so
treatment to halt the attacks can be given.”
Haick is the founder and
chief scientific officer of the Nanose Ltd., a leading developer of advanced
nanotechnology for cancer detection by breath analysis.
He received his
BSc. from Ben-Gurion University of the Negev and completed his PhD in chemical
engineering at the Technion in 2002. After a two-year period at the Weizmann
Institute of Science, he went to the California Institute of Technology-Caltech
for postdoctoral research and returned to the Technion in 2006. He has received
a Fulbright fellowship, the Science and Technology Ministry award, Prof.
Avrahami prize, and CNR-IMIP prize.